Dr Reddy's Laboratories reported a 3% revenue growth to ₹33,593.3 crore for FY2026, but net profit fell 26% to ₹4,246.6 crore. The company cited challenges like lenalidomide sales decline and price erosion in key markets.
Dr Reddy's Laboratories FY2026 Results
Consolidated Revenue: ₹33,593.3 crore
Profit After Tax (PAT): ₹4,246.6 crore
Reader Takeaway: Revenue growth offset by profit decline due to market pressures and one-off costs.
What just happened
Dr Reddy's Laboratories announced its financial results for Fiscal Year 2026, reporting consolidated revenues of ₹33,593.3 crore, a 3% increase over the previous year. However, the company's Profit After Tax (PAT) saw a significant decline of 26%, settling at ₹4,246.6 crore. EBITDA also decreased by 17% to ₹7,659.5 crore.
Why this matters
The results indicate a mixed performance. While the company managed to grow its top line, profitability was impacted by several factors. This includes the anticipated drop in lenalidomide sales in the US, price erosion in North America and Europe, and a one-time provision for employee benefits. The performance in key markets like North America saw a decline of 22% in revenue.
The backstory
For FY2025, Dr Reddy's had reported revenues of ₹32,553.5 crore and a Profit After Tax of ₹5,724.5 crore. The current fiscal year's results show a revenue growth of 3% but a substantial profit dip. The company has been strategically investing in its base business while also building future growth drivers.
What changes now
Dr Reddy's is focusing on strengthening its underlying business and expanding its pipeline through new product launches and filings. The company aims to grow its presence in India (16% growth in FY26), Europe (55% growth), and Emerging Markets (23% growth) while navigating challenges in North America. A dividend of ₹8 per equity share has been recommended for FY2026.
Risks to watch
Key risks include continued competitive intensity and price erosion in the API and North America generics businesses. The impact of declining lenalidomide revenues remains a significant factor. Adverse product mix and any further one-off provisions could also affect profitability.
Peer comparison
(No direct peer comparison data available in the filing. Peer performance would typically be compared against companies like Sun Pharmaceutical Industries, Cipla, and Zydus Lifesciences in terms of revenue growth and profitability metrics.)
Context metrics (time-bound)
- Revenue Growth (FY26 vs FY25): +3% to ₹33,593.3 crore
- PAT Decline (FY26 vs FY25): -26% to ₹4,246.6 crore
- EBITDA Decline (FY26 vs FY25): -17% to ₹7,659.5 crore
- North America Revenue Change (FY26 vs FY25): -22%
- India Revenue Growth (FY26 vs FY25): +16%
- Europe Revenue Growth (FY26 vs FY25): +55%
- Emerging Markets Revenue Growth (FY26 vs FY25): +23%
- Dividend Recommended: ₹8 per equity share for FY2026
What to track next
Investors will be watching the company's ability to counter price erosion in North America, the success of new product launches, and the growth momentum in emerging markets and India. Progress on biosimilars and innovation-led therapies will be key indicators for future growth.